Nurix Therapeutics (NRIX) Retained Earnings (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Retained Earnings data on file, last reported at -$1.2 billion in Q2 2026.

• On a quarterly basis, Retained Earnings fell 40.71% year-over-year to -$1.2 billion in Q2 2026; TTM through May 2026 was -$1.2 billion, a 40.71% decrease from a year earlier, with the FY2025 full-year figure at $105000.0, down 30.0% from the prior year.
• Retained Earnings for Q2 2026 stood at -$1.2 billion, down from -$1.1 billion in the prior quarter.
• Over the last five years, Retained Earnings for NRIX reached as high as $150000.0 in Q4 2024 and fell as low as -$1.2 billion in Q2 2026.
• Historically, Retained Earnings has averaged -$436.3 million across 5 years, with a median of -$454.1 million in 2023.
• Across the five-year window, Retained Earnings surged 100.03% in 2024 and slumped 227071.43% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$401.3 million in 2022, then slumped by 35.87% to -$545.2 million in 2023, then surged by 100.03% to $150000.0 in 2024, then decreased by 30.0% to $105000.0 in 2025, then sank by 1123847.62% to -$1.2 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.2 billion in Q2 2026, -$1.1 billion in Q1 2026, and $105000.0 in Q4 2025.